Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651542 | 0.86 | CD274 (0.57) | NAMPTCD274HDAC1HDAC6HDAC3 | |
| SCHEMBL5925523 | 0.85 | NAMPT (0.56) | NAMPTCD274HDAC1HDAC6CYP17A1 | |
| SCHEMBL21661749 | 0.83 | NAMPT (0.72) | NAMPTCD274MAPTHDAC6HDAC3 | |
| SCHEMBL14279941 | 0.83 | CD274 (0.60) | NAMPTCD274HDAC1HDAC6HDAC3 | |
| SCHEMBL21661941 | 0.83 | HDAC6 (0.63) | NAMPTCD274HDAC1HDAC6HDAC3 | |
| SCHEMBL5736115 | 0.83 | HDAC1 (0.60) | NAMPTMAPTKDM4EHIF1ASLC22A6 | |
| SCHEMBL9300423 | 0.82 | CYP17A1 (0.51) | NAMPTMAPTHDAC1HDAC6HDAC3 | |
| SCHEMBL8879852 | 0.82 | NAMPT (0.59) | NAMPTCD274MAPTKDM4EHIF1A | |
| SCHEMBL30552299 | 0.82 | NAMPT (0.53) | NAMPTCD274HDAC1HDAC6CYP17A1 | |
| SCHEMBL22461360 | 0.81 | NAMPT (0.65) | NAMPTCD274MAPTHDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20070043093-A1 | Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043093-A1 | Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same | GLP1R, GCGR, GIPR | NAMPT 2650/4885CD274 737/4885MAPT 4725/4885 |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | EPX, CCL11, ELANE | NAMPT 2976/4885CD274 3344/4885MAPT 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.